Total submissions: 14
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000727134 | SCV000565015 | benign | not provided | 2019-08-26 | criteria provided, single submitter | clinical testing | Has not been previously published in association with FLNC-related disorders to our knowledge; Reported in ClinVar but additional evidence is not available (ClinVar Variant ID# 418215; Landrum et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 26555887) |
Labcorp Genetics |
RCV001084196 | SCV000650907 | likely benign | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000727134 | SCV000706047 | uncertain significance | not provided | 2017-02-08 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000727134 | SCV002506084 | likely benign | not provided | 2023-08-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002395142 | SCV002705286 | benign | Cardiovascular phenotype | 2021-06-23 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
CHEO Genetics Diagnostic Laboratory, |
RCV003150234 | SCV003837892 | benign | Cardiomyopathy | 2021-12-29 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000727134 | SCV004224103 | uncertain significance | not provided | 2022-02-08 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000727134 | SCV004701401 | benign | not provided | 2024-04-01 | criteria provided, single submitter | clinical testing | FLNC: PP3, BS1, BS2 |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004525941 | SCV005040383 | likely benign | not specified | 2024-03-31 | criteria provided, single submitter | clinical testing | |
Clinical Genetics, |
RCV000727134 | SCV001923554 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000727134 | SCV001929972 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000727134 | SCV001954219 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000727134 | SCV001973555 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV004722814 | SCV005340582 | likely benign | FLNC-related disorder | 2024-03-26 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |